[Directed differentiation of human induced pluripotent stem cells into midbrain].
Xu J, Li Y, Zhong G, Fang Z, Liu C, Ma C, Wang C, Guo Y, Liu C
Researchers successfully differentiated human stem cells into midbrain dopaminergic neurons and transplanted them into rats with Parkinson's disease. The transplanted cells survived, integrated into the brain tissue, and significantly improved motor function in the animal model.
- Human stem cells differentiate efficiently into functional midbrain dopaminergic progenitors.
- Transplanted neurons survive and integrate into the host rat brain for at least eight weeks.
- Cell transplantation significantly improves motor deficits in Parkinson's disease rat models.
Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model.
Lai JI, Porcu A, Romoli B, Keisler M, Manfredsson FP, Powell SB, Dulcis D
Chronic nicotine exposure rescues motor deficits in a mouse model of Parkinson's disease by triggering GABAergic neurons to adopt a dopamine-producing phenotype. This effect relies on the upregulation of Nurr1 (NR4A2), suggesting that activating this pathway can protect or restore dopaminergic function.
- Nicotine increases Nurr1 and dopamine enzyme levels in specific brain neurons.
- Activating GABA neurons alone mimics these protective effects in mice.
- The study uses a Parkinson's mouse model, not human patients.
- NR4A2/Nurr1 is central to the observed neuronal plasticity.
Timing of MeCP2 Expression Determines Midbrain Dopamine Neuron Phenotype Specification.
He XB, Guo F, Li K, Yan J, Lee SH
Premature expression of the protein MeCP2 blocks the development of dopamine neurons by interfering with NURR1, a key regulator also affected in NR4A2 syndrome. This interference prevents the necessary DNA changes required for these brain cells to mature properly.
- MeCP2 interferes with NURR1 function during early neuron development.
- Premature MeCP2 blocks dopamine neuron specification in mouse models.
- Correct timing of MeCP2 is critical for proper brain cell maturation.
- This mechanism highlights a potential pathway relevant to NR4A2-related disorders.
Ukgansan Protects Dopaminergic Neurons against MPTP-Induced Neurotoxicity via the Nurr1 Signaling Pathway.
Chae IC, Jang JH, Seol IC, Kim YS, Park G, Yoo HR
Ukgansan, a traditional herbal remedy, protects dopaminergic neurons and improves motor symptoms in mice with Parkinson's-like damage by activating the Nurr1 pathway. This preclinical study demonstrates that the treatment reduces neuron loss and restores dopamine levels in an animal model of neurodegeneration.
- Ukgansan activates Nurr1, a protein critical for dopaminergic neuron survival.
- The treatment protects neurons from MPTP-induced toxicity in mice and cell cultures.
- Motor impairments and dopamine depletion improve following Ukgansan administration.
- This is preclinical evidence; no human clinical trials are reported.
Transplantation of human cord blood-derived multipotent stem cells (CB-SCs) enhances the recovery of Parkinson in rats.
Tang X, Li H, An B, Ma H, Huang N, Li X
Transplanting human cord blood stem cells into rats with Parkinson's disease promotes the growth of dopamine-producing neurons and improves motor symptoms. This preclinical study demonstrates that these stem cells can differentiate into dopaminergic cells and support behavioral recovery in an animal model.
- Cord blood stem cells express Nurr1, a transcription factor linked to NR4A2 biology.
- Transplanted cells largely committed to becoming dopamine neurons in rat brains.
- Treated rats showed improved motor function compared to control groups.
- Higher levels of surviving dopamine neurons were found in treated rats.
Prenatal Exposure to Gabapentin Alters the Development of Ventral Midbrain Dopaminergic Neurons.
Alsanie WF, Abdelrahman S, Alhomrani M, Gaber A, Habeeballah H, Alkhatabi HA, Felimban RI, Hauser CAE, Tayeb HH, Alamri AS, Raafat BM, Anwar S, Alswat KA, Althobaiti YS, Asiri YA
Prenatal exposure to gabapentin disrupts the development of dopaminergic neurons in fetal brain tissue by altering key genetic markers and reducing cell energy production. This suggests that using gabapentin during pregnancy may harm the formation of brain circuits relevant to NR4A2-related syndromes.
- Gabapentin alters gene expression critical for dopaminergic neuron development in fetal tissue.
- The drug reduces neurite length and halts ATP production in developing neurons.
- Findings are based on mouse embryo cell cultures, not human clinical data.
Embelin and levodopa combination therapy for improved Parkinson's disease treatment.
Ramachandra VH, Sivanesan S, Koppal A, Anandakumar S, Howell MD, Sukumar E, Vijayaraghavan R
This study shows that combining embelin with levodopa protects dopaminergic neurons and reduces gut damage in mice with Parkinson's disease. The treatment restores key proteins like Nurr1 and tyrosine hydroxylase, suggesting a potential therapeutic strategy for neurodegeneration.
- Embelin combined with levodopa reduces oxidative stress and gut damage in PD mice.
- The combination therapy restores Nurr1 and tyrosine hydroxylase protein levels in the midbrain.
- Molecular modeling confirms embelin binds to alpha-synuclein fibrils.
- Results suggest embelian may enhance levodopa efficacy in Parkinson's models.
Impaired Neurodevelopmental Genes in Slovenian Autistic Children Elucidate the Comorbidity of Autism With Other Developmental Disorders.
Krgovic D, Gorenjak M, Rihar N, Opalic I, Stangler Herodez S, Gregoric Kumperscak H, Dovc P, Kokalj Vokac N
This study identifies rare variants in the NR4A2 gene among children with autism spectrum disorder, confirming its role in neurodevelopmental conditions. The findings support the link between NR4A2 mutations and developmental disorders, providing genetic evidence relevant to your child's diagnosis.
- Researchers found NR4A2 variants in Slovenian children with suspected autism.
- The study used whole exome sequencing to identify rare genetic changes.
- NR4A2 is linked to neurodevelopmental disorders and intellectual disability.
- This adds to human genetic evidence for NR4A2-related syndromes.
Cannabis alters DNA methylation at maternally imprinted and autism candidate genes in spermatogenic cells.
Schrott R, Greeson KW, King D, Symosko Crow KM, Easley CA, Murphy SK
Paternal cannabis exposure alters DNA methylation at the NR4A2 gene in human sperm cells, which may contribute to autism risk in offspring. This study provides mechanistic insight into how environmental factors might affect NR4A2 function before conception.
- Cannabis changes DNA methylation at NR4A2 in human spermatogenic stem cells.
- This epigenetic alteration links paternal cannabis use to autism spectrum disorder risk.
- The study uses an in vitro model of human sperm development.
- Findings align with previous observations in human cohorts and rat models.
NURR1-deficient mice have age- and sex-specific behavioral phenotypes.
Montarolo F, Martire S, Chiara F, Allegra S, De Francia S, Hoxha E, Tempia F, Capobianco MA, Bertolotto A
Old male mice lacking one copy of the Nurr1 gene show specific motor impairments and changes in dopamine levels, while both sexes exhibit increased heart rate. These findings confirm that partial loss of this gene affects movement and cardiovascular function in aging animals, though results vary by sex for general activity.
- Old male mice with one missing Nurr1 copy show motor impairment.
- Both sexes show increased brain dopamine levels and heart rate.
- Spontaneous locomotor activity changes only affect male mice.
- Results confirm previous controversial findings about age-related deficits.
Nurr1 Modulation Mediates Neuroprotective Effects of Statins.
Willems S, Marschner JA, Kilu W, Faudone G, Busch R, Duensing-Kropp S, Heering J, Merk D
Statins directly activate the Nurr1 protein to reduce inflammation and improve metabolic health in brain cells. This study identifies a specific molecular mechanism by which statins protect neurons, suggesting they could potentially be repurposed for NR4A2-related conditions.
- Statins directly bind to and activate the Nurr1 transcription factor in lab settings.
- Activating Nurr1 reduces inflammation and improves glucose metabolism in neuronal cells.
- The study uses cell cultures, not human patients or animal models.
- No clinical trials or human data on statin efficacy for NR4A2 are presented.
Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (SYNGR3) Gene: The Effects of NURR1 on Its Expression.
Li L, Ho PW, Liu H, Pang SY, Chang EE, Choi ZY, Malki Y, Kung MH, Ramsden DB, Ho SL
This study shows that the protein NURR1 directly controls the expression of SYNGR3, a key component for dopamine transport in brain cells. Activating NURR1 increases SYNGR3 levels in neuronal cell lines, suggesting a potential mechanism to support dopamine function.
- NURR1 binds to specific DNA sites to regulate the SYNGR3 gene promoter.
- Mutating these binding sites reduces SYNGR3 expression in neuronal cells.
- A NURR1 activator increases SYNGR3 protein levels in lab-grown neurons.
- The findings link NURR1 function directly to dopamine vesicle machinery.
Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active.
Ni A, Ernst C
This study explains why dopaminergic neurons are fragile by linking their high energy needs to oxidative stress vulnerability, a mechanism relevant to NR4A2's role in neuron development. It proposes that the transcription factors driving these cells, including NR4A2, program them for high metabolism, which makes them susceptible to genetic or metabolic insults.
- SNpc dopaminergic neurons have high metabolic rates, increasing oxidative stress vulnerability.
- NR4A2 helps program midbrain progenitors for high ATP production during development.
- High energy demands may explain selective cell death in NR4A2-related disorders.
- The paper provides a cellular framework for understanding neuron fragility.
Association Between NR4A2 Gene Polymorphism and Depressive Symptoms and Antidepressant Effect.
Song X, Sun N, Zhang A, Lei L, Li X, Liu Z, Wang Y, Yang C, Zhang K
Specific variations in the NR4A2 gene correlate with distinct depressive symptoms and how well patients respond to antidepressant medication. This study identifies genetic markers that may predict treatment outcomes in adults with major depressive disorder.
- NR4A2 gene variants link to specific depression symptoms like retardation and anxiety.
- One variant predicts better response to standard antidepressant therapy.
- Study involves human patients, providing direct genetic association data.
- Focuses on psychiatric outcomes rather than motor or developmental phenotypes.
Nurr1 repression mediates cardinal features of Parkinson's disease in α-synuclein transgenic mice.
Argyrofthalmidou M, Spathis AD, Maniati M, Poula A, Katsianou MA, Sotiriou E, Manousaki M, Perier C, Papapanagiotou I, Papadopoulou-Daifoti Z, Pitychoutis PM, Alexakos P, Vila M, Stefanis L, Vassilatis DK
Reduced Nurr1 levels combined with high alpha-synuclein cause severe Parkinson-like symptoms in mice, including movement paralysis and neuron death. This study shows that the interaction between these two specific proteins drives disease pathology rather than either factor acting alone.
- Mice with both low Nurr1 and high alpha-synuclein develop severe movement disorders.
- These symptoms include rigid paralysis, kyphosis, and premature death.
- The condition responds to L-DOPA treatment in the animal model.
- High alpha-synuclein actively suppresses Nurr1 protein levels in the brain.
- Neither genetic factor alone causes the full disease phenotype.
Conditional deficiency of m6A methyltransferase Mettl14 in substantia nigra alters dopaminergic neuron function.
Teng Y, Liu Z, Chen X, Liu Y, Geng F, Le W, Jiang H, Yang L
Deleting the m6A methyltransferase Mettl14 in adult mouse brains impairs motor function and reduces dopamine production. This study identifies Nurr1 (NR4A2) as a downstream target affected by this molecular change, linking RNA modification to dopaminergic neuron health.
- Mettl14 deletion in mouse substantia nigra causes motor deficits and reduced locomotor activity.
- Loss of Mettl14 lowers m6A levels and decreases Tyrosine Hydroxylase, reducing dopamine synthesis.
- Nurr1 expression drops significantly when Mettl14 is deleted, linking RNA methylation to NR4A2 regulation.
- The study confirms m6A's role in maintaining adult dopaminergic neuron function in mice.
Trophoblast glycoprotein is a marker for efficient sorting of ventral mesencephalic dopaminergic precursors derived from human pluripotent stem cells.
Yoo JE, Lee DR, Park S, Shin HR, Lee KG, Kim DS, Jo MY, Eom JH, Cho MS, Hwang DY, Kim DW
Researchers identify a surface protein called TPBG that helps isolate healthy dopamine-producing cells from stem cells for potential Parkinson's disease treatments. Sorting these cells using TPBG increases the number of functional neurons in animal models and reduces the risk of tumor formation from remaining undifferentiated cells.
- TPBG marks ventral mesencephalic dopaminergic precursors derived from human stem cells.
- Sorting by TPBG enriches for FOXA2+ and LMX1A+ precursor cells.
- Transplanted sorted cells improve behavior in rodent Parkinson's models.
- TPBG-sorted grafts contain more mature dopamine neurons (TH+, NURR1+, PITX3+).
- Sorted grafts show fewer proliferating cells, suggesting lower tumor risk.
Nurr1 downregulation is caused by CREB inactivation in a Parkinson's disease mouse model.
Xu X, He X, Ma S, Li M, Huang Q
Inactivating the CREB protein causes Nurr1 levels to drop in a mouse model of Parkinson's disease. Restoring active CREB rescues Nurr1 expression and protects neurons from damage in these mice.
- CREB inactivation drives Nurr1 downregulation in this Parkinson's mouse model.
- Active CREB restores Nurr1 levels and provides neuroprotection in mice.
- This study uses an animal model, not human patients or clinical trials.
Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.
Itokazu Y, Fuchigami T, Morgan JC, Yu RK
In a mouse model of Parkinson's disease, intranasal gangliosides reduce toxic alpha-synuclein and restore the expression of tyrosine hydroxylase by recruiting the NR4A2 protein to its target gene. This suggests that ganglioside supplementation can epigenetically activate dopaminergic neuron function through NR4A2-mediated mechanisms. While this demonstrates a plausible biological pathway for NR4A2-dependent rescue, it remains preclinical evidence in animals.
- Intranasal GD3 and GM1 reduce alpha-synuclein levels in Parkinson's model mice.
- GM1 restores tyrosine hydroxylase expression via NR4A2 recruitment to the gene promoter.
- Gangliosides induce epigenetic activation of the TH gene through histone acetylation.
- The study uses an A53T alpha-synuclein overexpressing mouse model, not humans.
Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway.
Gao H, Wang D, Wang YL, Mao JP, Jiang S, Yang XL
Pramipexole improves motor symptoms in rats with Parkinson's disease by restoring Nurr1 levels and reducing neuroinflammation. This preclinical study demonstrates that the drug can rescue dopaminergic neuron loss through the Nurr1/NF-κB pathway.
- The study uses a rat model of Parkinson's disease induced by 6-OHDA.
- Pramipexole treatment improves motor behavior in these rats.
- The drug restores Nurr1 expression, which is typically reduced in this disease model.
- Pramipexole reduces neuroinflammation by inhibiting the NF-κB pathway.
Working memory deficits in schizophrenia are associated with the rs34884856 variant and expression levels of the NR4A2 gene in a sample Mexican population: a case control study.
Ruiz-Sánchez E, Jiménez-Genchi J, Alcántara-Flores YM, Castañeda-González CJ, Aviña-Cervantes CL, Yescas P, Del Socorro González-Valadez M, Martínez-Rodríguez N, Ríos-Ortiz A, González-González M, López-Navarro ME, Rojas P
In a Mexican cohort with schizophrenia, the NR4A2 rs34884856 variant links gene expression levels to auditory working memory performance. This finding suggests that specific genetic changes in NR4A2 influence cognitive function through altered gene activity.
- Study compares schizophrenia patients and healthy controls in a Mexican population.
- Researchers analyzed two NR4A2 variants and gene expression in blood cells.
- No significant difference found in variant frequencies or overall expression between groups.
- Patients with the rs34884856 homozygous variant show a link between expression and working memory.
The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.
Kambey PA, Chengcheng M, Xiaoxiao G, Abdulrahman AA, Kanwore K, Nadeem I, Jiao W, Gao D
A malaria drug called amodiaquine protects dopamine-producing neurons in mice with a Parkinson's disease model by activating specific stress-response pathways. This preclinical study demonstrates that the drug can improve motor behavior and preserve neuronal markers, suggesting a potential mechanism for neuroprotection.
- Amodiaquine improves movement deficits in mice with dopamine neuron loss.
- The drug protects neurons by increasing phosphorylated P38 MAPK levels.
- Protection occurs independently of the PI3K/AKT signaling pathway.
- This is a mouse model study, not human clinical evidence.
GDNF Therapy: Can We Make It Work?
Björklund A
This paper discusses how GDNF/NRTN gene therapy might work by restoring receptor levels in surviving dopamine neurons, potentially through an interaction with the NR4A2 protein Nurr1. It suggests that correcting under-dosing could make this approach effective for Parkinson's disease.
- GDNF/NRTN therapy may restore Ret receptor expression in surviving neurons.
- This mechanism likely depends on interaction with the transcription factor Nurr1.
- The study is a commentary on postmortem findings and prior clinical trials.
- It proposes that proper dosing could unlock therapeutic potential for dopamine loss.
Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors.
Qin H, Zhao AD, Sun ML, Ma K, Fu XB
Researchers successfully converted human skin cells into dopamine-producing neuron-like cells using a chemical cocktail of small molecules and proteins. This method avoids genetic manipulation, potentially reducing safety risks for future cell replacement therapies in neurodegenerative diseases like Parkinson's.
- Human fibroblasts convert to dopamine neuron-like cells with 95% efficiency using chemicals and proteins.
- The process skips the neural stem cell stage, reducing potential tumorigenic risks.
- Induced cells express key dopamine markers including NURR1 (NR4A2) and fire electrical signals.
- This offers a safer alternative to genetic modification for generating therapeutic neurons.
Parkinsonism in children: Clinical classification and etiological spectrum.
Leuzzi V, Nardecchia F, Pons R, Galosi S
This paper classifies childhood-onset parkinsonism into distinct clinical categories based on age, symptoms, and genetic causes. It identifies NR4A2 mutations as a specific genetic cause of parkinsonism that presents within the broader context of neurodevelopmental disorders.
- Childhood parkinsonism is rare and primarily driven by genetic alterations rather than adult-onset disease mechanisms.
- The authors propose a classification system based on age at onset, clinical features, and underlying etiology.
- NR4A2 mutations cause parkinsonism that emerges alongside generalized neurodevelopmental derangements.
- Other identified genetic causes include MECP2, SCN1A, and RAB39B variants.
Analysis of rare variants of autosomal-dominant genes in a Chinese population with sporadic Parkinson's disease.
Zheng R, Jin CY, Chen Y, Ruan Y, Gao T, Lin ZH, Dong JX, Yan YP, Tian J, Pu JL, Zhang BR
This study screens the NR4A2 gene in humans with sporadic Parkinson's disease to identify rare genetic variants. It finds that while NR4A2 variants are present, they do not show a statistically significant association with the disease in this specific Chinese cohort.
- Researchers sequenced 12 autosomal-dominant Parkinson's genes in 391 patients.
- NR4A2 was one of the genes analyzed for rare variants.
- LRRK2 variants showed a strong link to sporadic Parkinson's disease risk.
- NR4A2 variants did not reach statistical significance for association with the disease.
- The study confirms LRRK2's role but offers limited insight into NR4A2's function in this context.
PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.
Rajan S, Jang Y, Kim CH, Kim W, Toh HT, Jeon J, Song B, Serra A, Lescar J, Yoo JY, Beldar S, Ye H, Kang C, Liu XW, Feitosa M, Kim Y, Hwang D, Goh G, Lim KL, Park HM, Lee CH, Oh SF, Petsko GA, Yoon HS, Kim KS
Prostaglandins PGE1 and PGA1 bind directly to the NR4A2 protein (Nurr1) and activate its function, leading to neuroprotection in dopaminergic neurons. These compounds improve motor deficits in mouse models of Parkinson's disease by enhancing the expression of genes controlled by NR4A2.
- PGE1 and PGA1 bind covalently to the NR4A2 protein structure.
- This binding activates NR4A2 transcriptional function in dopaminergic neurons.
- The treatment shows neuroprotective effects in Parkinson's disease mouse models.
- Motor deficits improve when NR4A2 is activated by these prostaglandins.
Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
Steece-Collier K, Collier TJ, Lipton JW, Stancati JA, Winn ME, Cole-Strauss A, Sellnow R, Conti MM, Mercado NM, Nillni EA, Sortwell CE, Manfredsson FP, Bishop C
This study identifies striatal Nurr1 expression as a key molecular marker distinguishing levodopa-induced dyskinesia susceptibility in rats, challenging the previous assumption that FosB is the primary driver. The findings suggest that genetic differences in Nurr1 regulation may influence how individuals respond to levodopa treatment.
- Striatal Nurr1 mRNA increases only in rats susceptible to levodopa-induced dyskinesia.
- FosB expression rises in both susceptible and resistant rat strains, weakening its causal role.
- The study uses genetically distinct rat strains to model dyskinesia susceptibility differences.
- Results suggest reevaluating Nurr1's role in regulating movement side effects of levodopa.
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC, Steece-Collier K, Altwal F, Sandoval IM, Kordower JH, Collier TJ, Sortwell CE, West AR, Manfredsson FP
Elevated levels of the Nurr1 protein in the striatum drive the development of levodopa-induced dyskinesia, a movement disorder side effect. This study confirms that Nurr1 is not just a marker but a causative factor in this condition.
- Overexpressing Nurr1 causes severe dyskinesia even in rats resistant to it.
- Activating Nurr1 worsens existing dyskinesia symptoms in affected animals.
- Nurr1 alters neuron structure and firing patterns linked to movement disorders.
- Postmortem human tissue shows similar Nurr1 elevation in treated Parkinson's patients.
Pharmacological activation of Nr4a rescues age-associated memory decline.
Chatterjee S, Walsh EN, Yan AL, Giese KP, Safe S, Abel T
Activating the Nr4a2 gene with a specific compound improves memory in young mice and reverses age-related memory loss in older mice. This suggests that drugs targeting this genetic pathway might help cognitive function, though these results are currently limited to animal models.
- C-DIM12 activates Nr4a2 transcription factors in the brain.
- The drug enhances spatial memory in young healthy mice.
- It rescues memory deficits caused by aging in older mice.
- Findings are preclinical and do not involve human participants.
Dopamine neuron induction and the neuroprotective effects of thyroid hormone derivatives.
Lee EH, Kim SM, Kim CH, Pagire SH, Pagire HS, Chung HY, Ahn JH, Park CH
Researchers identify specific thyroid hormone derivatives that successfully induce the growth of dopamine neurons from stem cells and protect them from damage. These compounds work by activating NURR1, a protein critical for dopamine neuron development, without causing excessive thyroid stimulation. This suggests a potential new avenue for treating conditions involving dopamine neuron loss.
- Thyroid hormone derivatives induce dopamine neurons via NURR1 activation in rat cells.
- Two specific derivatives protect and restore dopamine neurons from neurotoxic damage.
- The compounds avoid excessive thyroid stimulation while promoting neuron maturation.
- This is preclinical work using rat neural precursor cells, not human trials.
Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Kandil EA, Sayed RH, Ahmed LA, Abd El Fattah MA, El-Sayeh BM
Albendazole protects dopaminergic neurons and restores motor function in a rat model of Parkinson's disease by activating Nurr1 and HIF-1α pathways. This preclinical study suggests that albendazole could potentially treat neurodegeneration linked to Nurr1 deficiency, though human evidence is currently lacking.
- Albendazole restores dopamine levels and motor skills in Parkinson's model rats.
- The drug activates Nurr1, a gene critical for dopaminergic neuron survival.
- Albendazole reduces neuroinflammation and alpha-synuclein accumulation in the brain.
- This is an animal study; human clinical trials have not yet occurred.
NURR1 deficiency is associated to ADHD-like phenotypes in mice.
Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A
Male mice lacking the NURR1 protein display hyperactivity and impulsivity that resemble ADHD symptoms. Treatment with methylphenidate, a standard ADHD medication, successfully reduces this hyperactive behavior in these mice.
- NURR1-deficient mice show increased spontaneous locomotor activity and new evidence of impulsive behavior.
- Methylphenidate treatment reverses the hyperactivity observed in NURR1-knockout male mice.
- Brain dopamine levels and midbrain dopaminergic neuron counts remain normal despite behavioral changes.
- The study confirms no anxiety, motor coordination issues, or memory deficits in these mice.
Conversion of Astrocytes and Fibroblasts into Functional Noradrenergic Neurons.
Li S, Shi Y, Yao X, Wang X, Shen L, Rao Z, Yuan J, Liu Y, Zhou Z, Zhang Z, Liu F, Han S, Geng J, Yang H, Cheng L
Researchers successfully convert human skin and brain cells into functional noradrenergic neurons using a specific set of seven transcription factors, including Nurr1. These reprogrammed cells exhibit key neuronal functions such as firing electrical signals and integrating into neural circuits after transplantation. This technique offers a potential pathway for generating patient-specific cells for disease modeling or future cell-based therapies.
- Seven transcription factors convert human fibroblasts and astrocytes into functional noradrenergic neurons.
- Reprogrammed neurons produce, release, and re-uptake noradrenaline correctly.
- Cells fire action potentials and receive synaptic inputs in culture.
- Transplanted cells survive and integrate into neural circuits in animal models.
- Method applies to human cells, suggesting potential for personalized disease modeling.
Complementation of dopaminergic signaling by Pitx3-GDNF synergy induces dopamine secretion by multipotent Ntera2 cells.
Eskandarian Boroujeni M, Aliaghaei A, Maghsoudi N, Gardaneh M
Engineered human stem cells secrete dopamine and improve motor function in rats with Parkinson's disease when treated with specific genes. This preclinical study demonstrates a potential cell therapy strategy for restoring dopaminergic signaling, which is relevant to the underlying biology of NR4A2-related syndromes. The findings do not provide direct evidence for treating human patients or specific NR4A2 variants.
- Human stem cells secrete dopamine after genetic engineering with Pitx3 and GDNF.
- Treated cells survive and improve motor coordination in Parkinson's rat models.
- The study uses animal models, not human clinical trials or patient data.
- Results suggest potential for cell replacement therapy but remain preclinical.
Generation of functional dopaminergic neurons from human spermatogonial stem cells to rescue parkinsonian phenotypes.
Yang H, Hao D, Liu C, Huang D, Chen B, Fan H, Liu C, Zhang L, Zhang Q, An J, Zhao J
Researchers successfully convert human spermatogonial stem cells into functional dopaminergic neurons that integrate into mouse brains and improve movement deficits in a Parkinson's disease model. This preclinical study demonstrates a new method for generating dopamine-producing cells but does not involve human patients or NR4A2-specific genetics.
- Human spermatogonial stem cells convert into functional dopaminergic neurons using a specific chemical induction protocol.
- Converted neurons express key markers like Nurr1 and release dopamine in response to stimulation.
- Transplanted cells survive, migrate, and reduce motor deficits in mice with Parkinsonian symptoms.
- The study uses mouse models of Parkinson's disease, not humans or NR4A2 syndromes.
Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.
Gottschalk CG, Roy A, Jana M, Kundu M, Pahan K
The drug gemfibrozil increases Nurr1 levels in dopaminergic neurons by activating PPARα, a mechanism confirmed in both cell cultures and live mice. This suggests that targeting the PPARα pathway could potentially boost Nurr1 expression to protect or support these specific brain cells.
- Gemfibrozil raises Nurr1 protein levels in dopaminergic neurons via PPARα activation.
- The effect disappears in mice lacking the PPARα gene, confirming the mechanism.
- Oral gemfibrozil increases Nurr1 in the mouse brain's substantia nigra region.
- This study provides preclinical proof that PPARα agonists can upregulate Nurr1.
Transplantation of Nurr1-overexpressing neural stem cells and microglia for treating parkinsonian rats.
Qian Y, Chen XX, Wang W, Li JJ, Wang XP, Tang ZW, Xu JT, Lin H, Yang ZY, Li LY, Song XB, Guo JZ, Bian LG, Zhou L, Lu D, Deng XL
Transplanting neural stem cells and microglia engineered to overexpress Nurr1 improves motor symptoms and increases dopamine neuron survival in rats with Parkinson's disease. This approach modifies the brain environment to support cell grafts, offering a potential future strategy for cell replacement therapy.
- Combined Nurr1-overexpressing stem cells and microglia improve behavior in Parkinsonian rats.
- The treatment increases dopamine-producing cells and reduces inflammatory markers in the brain.
- Transplanted dopamine neurons survive for at least five months after implantation.
- This is a preclinical animal study, not human clinical evidence.
Inhibition of Ezh2 In Vitro and the Decline of Ezh2 in Developing Midbrain Promote Dopaminergic Neurons Differentiation Through Modifying H3K27me3.
Hong F, Zhao M, Zhang L, Feng L
Inhibiting the enzyme Ezh2 promotes the development of dopamine-producing neurons by removing a specific repressive chemical mark on DNA. This effect depends entirely on Nurr1 (NR4A2), as blocking Nurr1 stops the beneficial outcome, confirming that Ezh2 regulates neuron formation through this pathway.
- Ezh2 inhibition increases dopamine neuron differentiation in stem cells and developing brains.
- The process requires Nurr1; blocking Nurr1 prevents the neuronal growth.
- Ezh2 removes a repressive mark (H3K27me3) to allow dopamine gene expression.
- This is preclinical research using cell cultures and animal models.
Altered Expression Levels of MicroRNA-132 and Nurr1 in Peripheral Blood of Parkinson's Disease: Potential Disease Biomarkers.
Yang Z, Li T, Li S, Wei M, Qi H, Shen B, Chang RC, Le W, Piao F
This study measures NR4A2 (Nurr1) and miR-132 levels in the blood of adults with Parkinson's disease to identify potential diagnostic biomarkers. It finds that NR4A2 levels are significantly lower in these patients compared to healthy controls, while miR-132 levels are higher, suggesting a link between these molecules and disease severity.
- NR4A2 protein levels are significantly decreased in the blood of Parkinson's patients.
- miR-132 levels are significantly elevated in Parkinson's patients compared to healthy controls.
- Higher miR-132 correlates with increased disease risk, stage, and severity in males.
- Low NR4A2 and high miR-132 form a potential biomarker profile for Parkinson's diagnosis.